Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal oxytocin as an adjunct to psycho-educational interventions for challenging behaviors in children with autism spectrum disorder and intellectual disability
2022-000254-28Phase 2Active
- Sponsor
- Centre hospitalier universitaire de Toulouse
- Start
- Jan 2022
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, single-arm trial of oxytocin in Autism Spectrum Disorder (ASD) and intellectual disability (ID), sponsored by Centre hospitalier universitaire de Toulouse. Primary endpoint: Protocol feasibility success rate. Started Jan 2022; status: active.
02
Drugs
oxytocin
03
Conditions
Autism Spectrum Disorder (ASD)intellectual disability (ID)
Beyond the preview
Go deeper on 2022-000254-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000254-28.